CORRIGENDA

Effect of silencing PARG in human colon carcinoma LoVo cells on the ability of HUVEC migration and proliferation

J Pan, NJS Fauzee, Y-I Wang, Y-T Sheng, Y Tang, J-Q Wang, W-q Wu, J-x Yan and J Xu

Cancer Gene Therapy (2013) **20**, 701–702; doi:10.1038/cgt.2013.75

Correction to: *Cancer Gene Therapy* (2012) **19**, 715–722; doi:10.1038/cgt.2012.48; published online 24 August 2012

Figures 1 and 2 in this article were published with errors. The correct figure parts, and their legends, are reproduced correctly here. The authors regret the errors.

Figure 1. (a) LoVo cells transfected with TurboGFP ($\times 400$). In all, 2, 5, 10 and 15 μ l of lentiviral particles containing TurboGFP were transfected into LoVo cells. After 48 h of incubation at 37 °C fluorescein was displayed in LoVo cells. (A) Represents 2 μ l of lentiviral particles containing the TurboGFP group, (B) 5, (C) 10 and (D) 15 μ l. (d and f) Effect of knockdown PARG by shRNA in LoVo cells. RT-PCR reveals complete inhibition of PARG expression in PARG-shRNA-transfected cells compared with untransfected and control-shRNA cells. β -Actin was used as an internal loading control.

Figure 2. (c and d) Western blot analysis highlights a decrease in expression of cytoplasmic p-IκBα together with a fall in the intranuclear expression of NF-κB in PARG-shRNA cells compared with both untransfected and control-shRNA cells (* $P < 0.05$).

Combining CAR T cells and the Bcl-2 family apoptosis inhibitor ABT-737 for treating B-cell malignancy

SCH Karlsson, AC Lindqvist, M Fransson, G Paul-Wetterberg, B Nilsson, M Essand, K Nilsson, P Frisk, H Jernberg-Wiklund and SIA Loskog

Cancer Gene Therapy (2013) **20**, 702; doi:10.1038/cgt.2013.76

Correction to: *Cancer Gene Therapy* (2013) **20**, 386–393; doi:10.1038/cgt/2013.35

Two of the authors were listed with incorrect initials. The first author should have been listed as H Karlsson. The last author should have been listed as A Loskog. The authors regret the errors.